Valeant extends expiration of offer to acquire Allergan

Valeant Pharmaceuticals announced it has delayed the expiration of its exchange offer to acquire all outstanding shares of Allergan to 5 p.m. EST on Dec. 31, 2014, from the originally scheduled expiration date of Aug. 15, 2014.

All other terms and conditions of the exchange offer will remain the same, according to a press release from Valeant.

The depositary of the exchange offer has advised that as of 9 a.m. EST on Aug. 15, 2014, approximately 12,509,606 shares of Allergan common stock were validly tendered and not properly withdrawn in the exchange offer, according to the release.

Valeant Pharmaceuticals announced it has delayed the expiration of its exchange offer to acquire all outstanding shares of Allergan to 5 p.m. EST on Dec. 31, 2014, from the originally scheduled expiration date of Aug. 15, 2014.

All other terms and conditions of the exchange offer will remain the same, according to a press release from Valeant.

The depositary of the exchange offer has advised that as of 9 a.m. EST on Aug. 15, 2014, approximately 12,509,606 shares of Allergan common stock were validly tendered and not properly withdrawn in the exchange offer, according to the release.